A PHASE II TRIAL OF ERLOTINIB VERSUS PEMETREXED AS SECOND-LINE THERAPY IN TREATING PATIENTS WITH ADVANCED EGFR WILD-TYPE AND EGFR FISH-POSITIVE LUNG ADENOCARCINOMA

被引：0
作者：
Wang, Si-Yu [1 ]
Li, Ning [1 ]
Ou, Wei [1 ]
Zhang, Liang [1 ]
Zhang, Song-Liang [1 ]
机构：
[1] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
non-small cell lung cancer; second-line;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.10-028
引用
收藏
页码：S575 / S575
页数：1
相关论文
共 50 条
  • [31] Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
    Markoczy, Zsolt
    Sarosi, Veronika
    Kudaba, Iveta
    Galffy, Gabriella
    Turay, Ulku Yilmaz
    Demirkazik, Ahmet
    Purkalne, Gunta
    Somfay, Attila
    Papai-Szekely, Zsolt
    Raso, Erzsebet
    Ostoros, Gyula
    BMC CANCER, 2018, 18
  • [32] Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
    Gervais, R
    Ducolone, A
    Breton, JL
    Braun, D
    Lebeau, B
    Vaylet, F
    Debieuvre, D
    Pujol, JL
    Tredaniel, J
    Clouet, P
    Quoix, E
    ANNALS OF ONCOLOGY, 2005, 16 (01) : 90 - 96
  • [33] Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial
    Gridelli, C
    Perrone, F
    Gallo, C
    Rossi, A
    Barletta, E
    Barzelloni, ML
    Creazzola, S
    Gatani, T
    Fiore, F
    Guida, C
    Scognamiglio, F
    ANTICANCER RESEARCH, 1999, 19 (5C) : 4535 - 4538
  • [34] A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
    Chihara, Yusuke
    Takeda, Takayuki
    Goto, Yasuhiro
    Nakamura, Yoichi
    Tsuchiya-Kawano, Yuko
    Nakao, Akira
    Onoi, Keisuke
    Hibino, Makoto
    Fukuda, Minoru
    Honda, Ryoichi
    Yamada, Takahiro
    Taniguchi, Ryusuke
    Sakamoto, Sinjiro
    Date, Koji
    Nagashima, Seiji
    Tanzawa, Shigeru
    Minato, Koichi
    Nakatani, Koichi
    Izumi, Miiru
    Shimose, Takayuki
    Kishimoto, Junji
    Uchino, Junji
    Takayama, Koichi
    ONCOLOGIST, 2022, 27 (11) : 903 - E834
  • [35] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumira, Tomohiro
    Matusura, Kuniomi
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    Hirata, Kazuto
    LUNG CANCER, 2015, 90 (01) : 65 - 70
  • [36] Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study)
    Lv, C.
    Wang, R.
    Li, S.
    Yan, S.
    Wang, Y.
    Chen, J.
    Wang, L.
    Liu, Y.
    Guo, Z.
    Wang, J.
    Pei, Y.
    Yu, L.
    Wu, N.
    Lu, F.
    Gao, F.
    Chen, J.
    Liu, Y.
    Wang, X.
    Li, S.
    Han, B.
    Zhang, L.
    Ma, Y.
    Ding, L.
    Wang, Y.
    Yuan, X.
    Yang, Y.
    ESMO OPEN, 2023, 8 (04)
  • [37] A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations Okayama Lung Cancer Study Group Trial 0705
    Yoshioka, Hiroshige
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    Takigawa, Nagio
    Hayashi, Hidetoshi
    Harita, Shingo
    Kuyama, Shoichi
    Segawa, Yoshihiko
    Kamei, Haruhito
    Umemura, Shigeki
    Bessho, Akihiro
    Tabata, Masahiro
    Tanimoto, Mitsune
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 99 - 104
  • [38] A multi-center phase II study of nintedanib as second-line therapy for patients with advanced non-small-cell lung cancer in China
    Dai, Wenxin
    Luo, Bailing
    Wu, Zhiyong
    Chen, Juan
    Feng, Guangqiu
    Guan, Ping
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (10): : 3270 - 3275
  • [39] First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
    Salazar, Fernanda
    Angel Molina, Miguel
    Sanchez-Ronco, Maria
    Moran, Teresa
    Luis Ramirez, Jose
    Miguel Sanchez, Jose
    Stahel, Rolf
    Garrido, Pilar
    Cobo, Manuel
    Isla, Dolores
    Bertran-Alamilloh, Jordi
    Massuti, Bartomeu
    Cardenal, Felipe
    Manegold, Christian
    Lianes, Pilar
    Manuel Trig, Jose
    Javier Sanchez, Jose
    Taron, Miquel
    Rosell, Rafael
    LUNG CANCER, 2011, 72 (01) : 84 - 91
  • [40] Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer
    Lai, CL
    Tsai, CM
    Chiu, CH
    Wang, GS
    Su, WJ
    Chen, YM
    Perng, RP
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (12) : 700 - 706
12345